Home  |   Archive  |   Online Submission  |   News & Events  |   Subscribe  |   APFA  |   Society  |   Contact Us  |   中文版
Search   
 
Journal

Ahead of print
Authors' Accepted
    Manuscripts
new!
Current Issue
Archive
Acknowledgments
Special Issues
Browse by Category

Manuscript Submission

Online Submission
Online Review
Instruction for Authors
Instruction for Reviewers
English Corner new!

About AJA

About AJA
Editorial Board
Contact Us
News

Resources & Services

Advertisement
Subscription
Email alert
Proceedings
Reprints

Download area

Copyright licence
EndNote style file
Manuscript word template
Guidance for AJA figures
    preparation (in English)

Guidance for AJA figures
    preparation (in Chinese)

Proof-reading for the
    authors

AJA Club (in English)
AJA Club (in Chinese)

 
Abstract

Volume 23, Issue 2 (March 2021) 23, 188–196; 10.4103/aja.aja_60_20

TGF-β1-regulated miR-3691-3p targets E2F3 and PRDM1 to inhibit prostate cancer progression

Yue-Mei Hu1,2,3, Xiao-Li Lou1,3, Bao-Zhu Liu3,4, Li Sun5, Shan Wan1, Lei Wu5, Xin Zhao1, Qing Zhou6, Mao-Min Sun5, Kun Tao2, Yong-Sheng Zhang7, Shou-Li Wang1,8

1 Department of Pathology, School of Biology and Basic Medical Sciences, Soochow University, Suzhou 215123, China
2 Department of Pathology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200336, China
3 Collaborative Innovation Center of Clinical Immunology between Soochow University and Sihong People's Hospital, Sihong 223900, China
4 Department of Pathology, Sihong People's Hospital, Sihong 223900, China
5 Laboratory Animal Research Center, Soochow University School of Medicine, Suzhou 215123, China
6 Department of Surgery, The First Affiliated Hospital of Soochow University, Suzhou 215006, China
7 Department of Pathology, The Second Affiliated Hospital of Soochow University, Suzhou 215004, China
8 Suzhou Key Laboratory of Tumor Microenvironment and Pathology, Soochow University, Suzhou 215006, China

Correspondence: Dr. SL Wang (wangsoly112@hotmail.com) or Dr. YS Zhang (shengyongzh@126.com)

Date of Submission 25-Dec-2019 Date of Acceptance 07-Aug-2020 Date of Web Publication 06-Nov-2020

Abstract

Transforming growth factor-β1 (TGF-β1) acts as a tumor promoter in advanced prostate cancer (PCa). We speculated that microRNAs (miRNAs) that are inhibited by TGF-β1 might exert anti-tumor effects. To assess this, we identified several miRNAs downregulated by TGF-β1 in PCa cell lines and selected miR-3691-3p for detailed analysis as a candidate anti-oncogene miRNA. miR-3691-3p was expressed at significantly lower levels in human PCa tissue compared with paired benign prostatic hyperplasia tissue, and its expression level correlated inversely with aggressive clinical pathological features. Overexpression of miR-3691-3p in PCa cell lines inhibited proliferation, migration, and invasion, and promoted apoptosis. The miR-3691-3p target genes E2F transcription factor 3 (E2F3) and PR domain containing 1, with ZNF domain (PRDM1) were upregulated in miR-3691-3p-overexpressing PCa cells, and silencing of E2F3 or PRDM1 suppressed PCa cell proliferation, migration, and invasion. Treatment of mice bearing PCa xenografts with a miR-3691-3p agomir inhibited tumor growth and promoted tumor cell apoptosis. Consistent with the negative regulation of E2F3 and PRDM1 by miR-3691-3p, both proteins were overexpressed in clinical PCa specimens compared with noncancerous prostate tissue. Our results indicate that TGF-β1-regulated miR-3691-3p acts as an anti-oncogene in PCa by downregulating E2F3 and PRDM1. These results provide novel insights into the mechanisms by which TGF-β1 contributes to the progression of PCa.

Keywords: E2F transcription factor 3; miR-3691-3p; PR domain containing 1, with ZNF domain; prostate cancer; transforming growth factor-β1

Full Text | PDF |

 
Browse:  747
 
Asian Journal of Andrology CN 31-1795/R ISSN 1008-682X  Copyright © 2023  Shanghai Materia Medica, Chinese Academy of Sciences.  All rights reserved.